

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

LISTING OF CLAIMS:

1. (Currently amended) A recombinant MVA containing and capable of expressing ~~one or more~~ at least one DNA sequence encoding a dengue virus antigenic epitope.

2-34. (Cancelled)

35. (Currently amended) The recombinant MVA according to claim 1, wherein the DNA sequence is selected from the group consisting of a DNA sequence encoding a Dengue virus serotype 1 antigenic epitope, a DNA sequence encoding a Dengue virus serotype 2 antigenic epitope, a DNA sequence encoding a Dengue virus serotype 3 antigenic epitope, and a DNA sequence encoding a Dengue virus serotype 4 antigenic epitope.

36. (Currently amended) The recombinant MVA according to claim 35, wherein the DNA sequence encodes a Dengue virus serotype 2 antigenic epitope.

37. (Currently amended) The recombinant MVA according to claim 1, wherein the DNA sequence is selected from the group consisting of a DNA sequence encoding a preM antigen epitope, a DNA sequence encoding an E antigen epitope, ~~or~~ and a DNA sequence encoding an NS1 antigen epitope.

38. (Previously presented) The recombinant MVA according to claim 1, wherein the DNA sequence is inserted into a site of a naturally occurring deletion within the MVA genome.

39. (Previously presented) The recombinant MVA according to claim 38, wherein the DNA sequence is inserted into deletion site II.

40. (Previously presented) The recombinant MVA according to claim 1, wherein the DNA sequence is under transcriptional control of the vaccinia virus early/late promoter P7.5.

41. (Previously presented) A composition comprising the recombinant MVA according to claim 1 and a pharmaceutically acceptable carrier or diluent.

42. (Previously presented) A method for generating an immune response in an animal comprising administering to the animal the composition according to claim 41.

43. (Previously presented) The method according to claim 42, wherein the animal is a human.

44. (Previously presented) A cell comprising the recombinant MVA according to claim 1.

45. (Previously presented) The cell according to claim 44, wherein the cell is a eukaryotic cell.

46. (Previously presented) A method for the preparation of a recombinant MVA comprising culturing the cell according to claim 45 under suitable conditions and isolating the recombinant viral particles.